Physician profile
Arun Kumar
NPI 1538125372
$30,736.38
in general payments reported to CMS, 2019-2025
31 companies · $493 in 2025
The $493 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,207 · 2020: $2,038 · 2021: $6,636 · 2022: $5,123 · 2023: $5,347 · 2024: $3,891 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,083 · Food and Beverage: $1,095 · Travel and Lodging: $278 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,082.50 |
| Food and Beverage | $1,094.81 |
| Travel and Lodging | $278.33 |
| Education | $275.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $10,903.79 | 2019-2024 | Imfinzi, Truqap, Calquence |
| Incyte Corporation | $10,546.40 | 2019-2025 | Jakafi, Zynyz |
| Daiichi Sankyo INC. | $2,396.49 | 2019-2023 | Enhertu |
| Beigene USA, INC. | $1,602.00 | 2022-2024 | Brukinsa |
| Tg Therapeutics, INC. | $1,526.25 | 2021 | |
| Abbvie INC. | $700.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $650.00 | 2020-2021 | |
| Novocure Gmbh | $500.00 | 2022 | |
| Cardinal Health 110 LLC | $375.00 | 2020-2025 | |
| Athenex Pharmaceutical Division, LLC | $150.00 | 2020 | |
| Karyopharm Therapeutics INC. | $133.96 | 2023-2024 | Xpovio |
| Dova Pharmaceuticals | $125.00 | 2020 | |
| Rigel Pharmaceuticals, INC. | $113.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.56 | 2019-2020 | |
| Tempus Ai, INC | $100.00 | 2025 | Xt Cdx |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $99.95 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $95.23 | 2019 | |
| Amgen INC. | $92.29 | 2019 | |
| Genentech USA, INC. | $73.13 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $72.81 | 2019 | |
| Mallinckrodt Enterprises LLC | $67.10 | 2019 | |
| Agios Pharmaceuticals, INC. | $64.55 | 2019 | |
| Merck Sharp & Dohme LLC | $54.17 | 2019 | |
| Valeritas, INC. | $45.83 | 2019 | |
| Exelixis INC. | $36.48 | 2019 | |
| Pfizer INC. | $26.11 | 2019 | |
| Genzyme Corporation | $25.00 | 2019 | |
| Tesaro, INC. | $14.29 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $13.63 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.94 | 2019 | |
| Clovis Oncology, INC. | $8.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.